Lower GI 2017

First page Table of contents Previous page 1054 Next page Last page

Pembrolizumab a humanized monoclonal antibody against PD-1 25 heavily pretreated patients with PD-L1-positive advanced SCCA Overall response rate of 5/25 (20%) Stable disease in a further 10/25 patients (40%)

(Ott P et al. Preliminary safety and efficacy results from KEYNOTE-028 ESMO 2015).

Made with